Table 3.
Bologna study cohort: patient and surgery characteristics according to TCGA classification.
| All Cases n = 117 | POLE ECs n = 8 | MMRd ECs n = 34 | P53 ECs n = 30 | NSMP ECs n = 45 | p Value | |
|---|---|---|---|---|---|---|
| Mean age, years (± SD) | 62.8 ± 10.7 | 59.6 ± 13 | 63.9 ±10.5 | 65.6 ± 9.4 | 60.9 ±11.1 | 0.207 |
| Mean BMI (± SD) | 27.7 ± 6.7 | 25.8 ± 4.7 | 26.7 ± 6.5 | 25.2 ± 3.9 | 30.2 ± 7.9 | 0.009 |
| HRT | ||||||
| Yes | 16 (13.7%) | 2 (25%) | 5 (14.7%) | 5 (16.7%) | 4 (8.9%) | 0.602 |
| No | 97 (82.9%) | 6 (75%) | 28 (82.4%) | 24 (80%) | 39 (86.7%) | |
| NA | 4 (3.4%) | 0 (%) | 1 (2.9%) | 1 (3.3%) | 2 (4.4%) | |
| Hypertension | 0.044 | |||||
| Yes | 62 (53%) | 1 (12.5%) | 18 (52.9%) | 14 (46.7%) | 29 (64.4%) | |
| No | 55 (47%) | 7 (87.5%) | 16 (47.1%) | 16 (53.3%) | 16 (35.6%) | |
| Diabetes | 0.025 | |||||
| Yes | 15 (12.8%) | 1 (12.5%) | 2 (5.9%) | 1 (3.3%) | 11 (24.4%) | |
| No | 102 (87.2%) | 7 (87.5%) | 32 (94.1%) | 29 (96.7%) | 34 (75.6%) | |
| Metformin use | 0.101 | |||||
| Yes | 13 (11.1%) | 1 (12.5%) | 2 (5.9%) | 1 (3.3%) | 9 (20%) | |
| No | 103 (88%) | 7 (87.5%) | 32 (94.1%) | 28 (93.4%) | 36 (80%) | |
| NA | 1 (0.9%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | |
| Hysteroscopic localization of EC | 0.581 | |||||
| Focal | 31 (26.5%) | 2 (%) | 12 (%) | 5 (16.7%) | 12 (26.7%) | |
| Multifocal | 39 (33.3%) | 4 (%) | 10 (%) | 10 (33.3%) | 15 (33.3%) | |
| NA | 47 (40.2%) | 2 (%) | 12 (%) | 15 (50%) | 18 (40%) | |
| ESMO risk group | 0.164 | |||||
| Low | 15 (12.8%) | 1 (12.5%) | 6 (17.6%) | 0 (0%) | 8 (17.8%) | |
| Intermediate | 8 (6.9%) | 0 (0%) | 4 (11.8%) | 1 (3.3%) | 3 (6.7%) | |
| High–intermediate | 35 (29.9%) | 2 (25%) | 7 (20.6%) | 2 (6.7%) | 24 (53.3%) | |
| High | 59 (50.4%) | 5 (62.5%) | 17 (50%) | 27 (90%) | 10 (22.2%) | |
| PORTEC risk group | 0.236 | |||||
| Low | 32 (27.4%) | 8 (100%) | 0 (0%) | 0 (0%) | 24 (53.3%) | |
| Intermediate | 36 (30.7%) | 0 (0%) | 23 (67.6%) | 0 (0%) | 13 (28.9%) | |
| High | 49 (41.9%) | 0 (0%) | 11 (32.4%) | 30 (100%) | 8 (17.8%) | |
| Lymphadenectomy | 0.01 | |||||
| Yes | 92 (78.6%) | 8 (100%) | 27 (79.4%) | 28 (93.3%) | 29 (64.4%) | |
| No | 25 (21.4%) | 0 (0%) | 7 (20.6%) | 2 (6.7%) | 16 (35.6%) | |
| Synchronous EC-OC | 0.281 | |||||
| Yes | 8 (6.8%) | 1 (12.5%) | 0 (0%) | 3 (10%) | 4 (8.9%) | |
| No | 104 (88.9%) | 6 (75%) | 33 (97.1%) | 26 (86.7%) | 39 (86.7%) | |
| NA | 5 (4.3%) | 1 (12.5%) | 1 (2.9%) | 1 (3.3%) | 2 (4.4%) |
BMI: body mass index; EC-OC: endometrial cancer–ovarian cancer; ESMO: European Society for Medical Oncology; HRT: hormonal replacement therapy; MMRd: mismatch repair deficiency; NA: not available; NSMP: no specific molecular profile; PORTEC: Post-Operative Radiation Therapy in Endometrial Carcinoma; TCGA: The Cancer Genome Atlas. Bold highlights the statistical significance.